Other Products → LIPOLYSIS
WEGOVY
Semaglutide (0.25 mg / 0.5 mg / 1 mg / 1.7 mg / 2.4 mg)
WEGOVY® is a once-weekly prescription medicine containing semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk for chronic weight management alongside diet and physical activity.
Categories
+
Effects
+
Supports weight loss and long-term weight management by regulating appetite, increasing satiety, reducing hunger, and helping decrease food intake.
SPEC
+
1 Pen
Content
+
Active Ingredient: Semaglutide
Available Doses: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg
Once-weekly subcutaneous injection
1 pre-filled pen per box
4 disposable needles per box
Price
+
Pricing may vary depending on the order quantity and business requirements. Our sales team is ready to assist you with current pricing and availability. Feel free to contact us anytime.
